Dare Bioscience Inc (DARE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.62-5.73%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · DARE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | — | 1.0 | 0.0 | 2.8 | 10.0 | — | — | — | — | — | 0.8 | 0.1 | 0.1 |
| Total Revenues | — | — | — | 2.8 | 10.0 | — | — | — | — | — | 0.8 | 0.1 | 0.1 |
| Cost of Revenues | — | 0.3 | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||||
| Selling, General & Admin | — | 8.8 | — | — | — | — | — | — | — | — | — | — | — |
| R&D Expenses | 2.7 | 5.5 | 14.2 | 21.5 | 30.0 | 30.6 | 20.8 | 8.5 | 6.4 | 1.0 | 0.1 | 25.9 | 11.8 |
| Operating Income | (11.1) | (13.6) | (23.5) | (30.9) | (31.4) | (39.1) | (27.4) | (14.3) | (16.9) | (11.2) | — | — | — |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | 0.3 | 0.0 | 2.4 | 1.1 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | 0.1 | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | (0.0) | 2.4 | 1.1 |
| Other Non-Operating Income / Expenses | — | — | — | — | — | — | — | — | — | — | (2.2) | (2.4) | — |
| EBT, Incl. Unusual Items | — | (13.5) | (4.1) | (30.2) | (30.9) | (38.7) | (27.4) | (14.3) | (16.8) | (11.5) | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Net Income | |||||||||||||
| Net Income | (11.0) | (13.4) | (4.1) | (30.2) | (30.9) | (38.7) | (27.4) | (14.3) | (16.7) | (11.5) | (0.7) | (39.6) | (23.3) |
| Per Share | |||||||||||||
| Basic EPS | (0.74) | (1.20) | (0.48) | (4.15) | (0.37) | (0.63) | — | — | — | — | — | — | — |
| Diluted EPS | (0.74) | (1.20) | (0.48) | (4.15) | (0.37) | (0.63) | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 14.9 | 11.2 | 8.5 | 7.3 | 84.6 | 61.2 | — | — | — | 3.2 | — | — | — |
| Diluted Weighted Avg Shares | 14.9 | 11.2 | 8.5 | 7.3 | 84.6 | 61.2 | — | — | — | 3.2 | — | — | — |
| Supplemental | |||||||||||||
| EBITDA | — | (11.9) | — | — | — | — | — | — | — | — | — | — | — |
| EBIT | (11.1) | (13.6) | (23.5) | (30.9) | (31.4) | (39.1) | (27.4) | (14.3) | (16.9) | (11.2) | — | — | — |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -0.0% | 0.0% | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.